30 Day Trial

Vericel's MACI Shows Sustained Benefit at Five Years

Share:

Study results demonstrated that improvements in pain and function from use of Vericel's MACI vs. microfracture in the treatment of knee cartilage defects were sustained for five years following surgery.

In the 2-year Phase III SUMMIT study (Superiority of MACI Implant Versus Microfracture Treatment), MACI autologous cultured chondrocytes on porcine collagen membrane demonstrated significantly greater improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) pain and function scores vs. microfracture.

The SUMMIT Extension was a 3-year follow-up of SUMMIT, for a total of up to five years of observation post-surgery.  Of the 144 patients randomized in the SUMMIT study, 128 (89%) continued observation out to five years in the extension.  Evaluation of these patients showed sustained improvement in KOOS pain and function.  A post‑hoc evaluation showed that the significantly greater improvement of MACI vs. microfracture observed at two years was maintained at five years.

The Extension is reported to be the first study in the field of cartilage repair to provide long-term, 5-year follow-up results from a successful multicenter, superiority study vs. microfracture.

Source: Vericel Corporation